Sergio Amadori
Overview
Explore the profile of Sergio Amadori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
191
Citations
10507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlenk R, Montesinos P, Kim H, Romero-Aguilar A, Vrhovac R, Patkowska E, et al.
Haematologica
. 2025 Mar;
PMID: 40079105
QuANTUM-First (NCT02668653) was a randomized phase 3 trial in newly diagnosed FLT3-ITDQpositive acute myeloid leukemia (AML) patients treated with quizartinib or placebo plus standard induction and consolidation chemotherapy and/or allogeneic...
2.
Baron F, Efficace F, Cannella L, Stevens-Kroef M, Amadori S, de Witte T, et al.
Am J Hematol
. 2024 Jan;
99(3):486-489.
PMID: 38174977
We report here the long-term follow-up of the only prospective randomized trial of autologous hematopoietic stem cell transplantation (auto-HSCT) with peripheral blood stem cells (APBSCT) versus auto-HSCT with bone marrow...
3.
Lubbert M, Wijermans P, Kicinski M, Chantepie S, van der Velden W, Noppeney R, et al.
Lancet Haematol
. 2023 Nov;
10(11):e879-e889.
PMID: 37914482
Background: Many older patients with acute myeloid leukaemia die or cannot undergo allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by intensive chemotherapy. We hypothesised that replacing intensive chemotherapy...
4.
De Muro M, Janssen A, Amadori S, de Fabritiis P, Sabatino D, Niscola P, et al.
Ther Adv Hematol
. 2023 Sep;
14:20406207231190683.
PMID: 37693118
Background: Hematological patients are a highly vulnerable population with an increased risk of developing severe COVID-19 symptoms due to their immunocompromised status. COVID-19 has proven to cause serious mental health...
5.
Erba H, Montesinos P, Kim H, Patkowska E, Vrhovac R, Zak P, et al.
Lancet
. 2023 Apr;
401(10388):1571-1583.
PMID: 37116523
Background: Patients with acute myeloid leukaemia (AML) positive for internal tandem duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent, selective, type 2 FLT3 inhibitor, plus...
6.
Mannelli F, Guglielmelli P, Fazi P, Crea E, Piciocchi A, Vignetti M, et al.
Future Oncol
. 2023 Jan;
19(2):103-111.
PMID: 36651780
The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 ...
7.
Jahn N, Jahn E, Saadati M, Bullinger L, Larson R, Ottone T, et al.
Leukemia
. 2022 Aug;
36(9):2218-2227.
PMID: 35922444
The aim of this study was to characterize the mutational landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the randomized CALGB 10603/RATIFY trial evaluating intensive chemotherapy plus...
8.
Messina M, Piciocchi A, Ottone T, Paolini S, Papayannidis C, Lessi F, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740677
IDH1/2 mutations are common in acute myeloid leukemia (AML) and represent a therapeutic target. The GIMEMA AML1516 observational protocol was designed to study the prevalence of IDH1/2 mutations and associations...
9.
Rucker F, Du L, Luck T, Benner A, Krzykalla J, Gathmann I, et al.
Leukemia
. 2021 Jul;
36(1):90-99.
PMID: 34316017
In acute myeloid leukemia (AML) internal tandem duplications of the FLT3 gene (FLT3-ITD) are associated with poor prognosis. Retrospectively, we investigated the prognostic and predictive impact of FLT3-ITD insertion site...
10.
Mannelli F, Gianfaldoni G, Guglielmelli P, Buccisano F, Caporale R, Chiarini M, et al.
Future Oncol
. 2021 Jul;
17(29):3787-3796.
PMID: 34254530
AMELIORATE is a Phase III, randomized trial aiming to personalize treatment intensity in -mutated acute myeloid leukemia. The current study provides an early appraisal of chemosensitivity based on peripheral blasts...